The Drug-Induced Respiratory Disease Website

Trastuzumab

Cardiomyopathy (acute, subacute, chronic)

Can be acute or subacute in onset. Severity is from the asymptomatic/subclinical state to overt heart failure. May cause acute or chronic left ventricular dysfunction, congestive heart failure (XIIIa) or cardiogenic pulmonary edema (IId). In some cases, will improve with drug stoppage

Publications

Hamdan D, Darrouzain F, Bejan-Angoulvant T, Isorni C, Zelek L, Paintaud G, Janin A, Bousquet G

A novel way to manage trastuzumab cardiotoxicity.

Cancer chemotherapy and pharmacology 2018 04;81;791-796 — 2018 04 — 791-796

Minichillo S, Gallelli I, Barbieri E, Cubelli M, Rubino D, Quercia S, Dall'Olio M, Rapezzi C, Zamagni C

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.

BMC cancer 2017 Nov 07;17;722 — 2017 Nov 07 — 722

Vasiliadis I, Kolovou V, Kolovou G

Acute cardiotoxic effects of adjuvant trastuzumab treatment.

Angiology 2014 Nov;65;950 — 2014 Nov — 950

Aldiab A

Cardiotoxicity with adjuvant trastuzumab use in breast cancer: A single institution's experience.

Journal of the Saudi Heart Association 2010 Jul;22;133-6 — 2010 Jul — 133-6

Guglin M, Hartlage G, Reynolds C, Chen R, Patel V

Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study.

Journal of cardiac failure 2009 Oct;15;651-7 — 2009 Oct — 651-7

Tu CM, Chu KM, Yang SP, Cheng SM, Wang WB

Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review.

The American journal of emergency medicine 2009 Sep;27;903.e1-3 — 2009 Sep — 903.e1-3

Diagnosing DIRD